Examination of Immune Checkpoints and Some of their Inhibitors Using Proteomics

Emberly Kincaid^*
*Correspondence: Emberly Kincaid, Department of Pathology, University of Porto, Porto, Portugal, Email:

Introduction

Immunotherapy has revolutionized cancer treatment by harnessing the body's own immune system to identify and destroy cancer cells. Central to this approach is the study of immune checkpoints, regulatory molecules that play a critical role in maintaining immune homeostasis and preventing autoimmunity. Immune checkpoints, such as programmed cell death protein 1 (PD-1), Cytotoxic T-lymphocyte-Associated antigen 4 (CTLA-4), and others, are negative regulators of the immune response, serving as brakes that cancer cells often exploit to evade immune destruction. Inhibitors targeting these checkpoints, known as Immune Checkpoint Inhibitors (ICIs), have shown remarkable clinical success in treating various types of cancers, including melanoma, lung cancer, and more [1].

Proteomics, the large-scale study of proteins, has emerged as an essential tool in the study of immune checkpoints. Through proteomic analyses, researchers can obtain comprehensive insights into protein expression, modifications, and interactions, which are crucial for understanding the mechanisms underlying immune checkpoint regulation and inhibition. By examining the proteomic landscapes associated with immune checkpoint molecules, researchers can identify biomarkers for predicting responses to immunotherapy, potential new drug targets, and mechanisms of resistance. This article explores the role of immune checkpoints in cancer, discusses key immune checkpoint inhibitors, and describes how proteomic techniques are advancing our understanding of immune checkpoint regulation and the therapeutic landscape [2].

Description

The immune system is equipped with complex regulatory mechanisms to differentiate between self and non-self antigens, thereby ensuring that immune responses are precisely modulated. Among these regulatory mechanisms are immune checkpoints, which serve as "checkpoints" that either stimulate or inhibit immune responses. In healthy individuals, these checkpoints are essential for preventing autoimmunity and maintaining immune homeostasis. However, in cancer, tumor cells can co-opt these checkpoints to evade immune surveillance, allowing them to grow unchecked. This ability of tumors to exploit immune checkpoints makes them a prime target for therapeutic interventions. Immune checkpoints can broadly be classified into inhibitory and stimulatory checkpoints. Inhibitory checkpoints, such as PD-1 and CTLA-4, function as brakes on the immune response, preventing overactivation of T-cells and thus protecting normal tissues from immune-mediated damage. However, in the tumor microenvironment, cancer cells can upregulate ligands such as PD-L1 and B7-1/B7-2 to engage these checkpoints, leading to the suppression of cytotoxic T-cell responses against tumors. On the other hand, stimulatory checkpoints like 4-1BB (CD137) and OX40 (CD134) are involved in enhancing T-cell responses, making them attractive targets for cancer immunotherapy aimed at boosting the immune response against cancer cells [3].

Proteomics, the large-scale study of proteins and their functions, has revolutionized our ability to analyze and understand complex biological processes. Through techniques such as Mass Spectrometry (MS), protein microarrays, and high-throughput screening, proteomics provides insights into protein expression levels, Post-Translational Modifications (PTMs), and protein-protein interactions within the immune system. When applied to the study of immune checkpoints, proteomics allows for an in-depth examination of the molecular and cellular mechanisms that regulate these pathways. Additionally, proteomics can reveal the impact of immune checkpoint inhibitors on tumor cells and the immune microenvironment, helping to identify biomarkers of response and resistance to therapy. One of the primary goals of proteomic analysis in immune checkpoint research is to profile the expression of checkpoint molecules and their associated signaling pathways. For example, MS-based proteomic studies have identified key PTMs, such as phosphorylation, ubiquitination, and glycosylation, on immune checkpoint proteins like PD-1 and CTLA-4 [4].

Despite the promising applications of proteomics in studying immune checkpoints, several challenges remain. One of the primary challenges is the complexity and diversity of the immune response, which varies not only between individuals but also across different tumor microenvironments. Tumor heterogeneity poses a significant obstacle to the identification of reliable biomarkers, as different cell populations within a tumor may respond differently to ICIs. Moreover, the high cost and technical complexity of proteomics limit its accessibility in routine clinical settings, necessitating further advancements in technology and cost-effectiveness. Integrating proteomics with other omics approaches, such as genomics and transcriptomics, holds great promise for enhancing our understanding of immune checkpoints. Multi-omics approaches can provide a more holistic view of immune responses and reveal novel biomarkers and therapeutic targets [5].

Conclusion

The study of immune checkpoints and their inhibitors has significantly advanced our understanding of cancer immunotherapy and opened new possibilities for therapeutic interventions in various diseases. Immune checkpoints, while essential for maintaining immune balance, can be exploited by cancer cells to evade immune detection, highlighting the importance of ICIs in restoring immune function. Through the use of proteomics, researchers are uncovering the molecular intricacies of immune checkpoint regulation and identifying biomarkers that can predict response to therapy. Proteomics enables a comprehensive analysis of protein expression, modifications, and interactions, shedding light on the complex mechanisms underlying ICI efficacy and resistance.

Despite the challenges associated with proteomic research, including tumor heterogeneity and technical limitations, ongoing advancements in proteomic technology and bioinformatics are making it an indispensable tool in immunology and oncology research. By integrating proteomics with other omics approaches, scientists can gain a deeper understanding of immune checkpoints and their role in disease, paving the way for more effective and personalized immunotherapies. As our knowledge of immune checkpoints continues to grow, proteomics will remain at the forefront of efforts to improve cancer treatment outcomes and develop novel strategies to harness the immune system for therapeutic benefit.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Aggarwal, Vaishali, Creg J. Workman and Dario AA Vignali. "LAG-3 as the third checkpoint inhibitor." Nat Immunol 24 (2023): 1415-1422.

Google Scholar, Crossref, Indexed at

2. Huo, Jin-Ling, Ya-Tao Wang, Wen-Jia Fu and Nan Lu, et al. "The promising immune checkpoint LAG-3 in cancer immunotherapy: From basic research to clinical application." Front Immunol 13 (2022): 956090.

Google Scholar, Crossref, Indexed at

3. Wang, Feng, Qi Zhao, Ying-Nan Wang and Ying Jin, et al. "Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types." JAMA Oncol 5 (2019): 1504-1506.

Google Scholar, Crossref, Indexed at

4. Gjoerup, Ole, Charlotte A. Brown, Jeffrey S. Ross and Richard SP Huang, et al. "Identification and utilization of biomarkers to predict response to immune checkpoint inhibitors." AAPS J 22 (2020): 1-15.

Google Scholar, Crossref, Indexed at

5. Bakheet, Tala M. and Andrew J. Doig. "Properties and identification of human protein drug targets." Bioinformatic 25 (2009): 451-457.

Google Scholar, Crossref, Indexed at